Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
